Douglas Michael Ackermann

Dr. Douglas Michael Ackermann serves as Director of Biotechnology for the Stanford University Byers Center for Biodesign. He is a Co-Founder and Board Member of Presidio Medical.  He was previously a Co-Founder and Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS), and Oyster Point Pharma, Inc. (NASDAQ: OYST, acquired by Viatris in 2023). Prior to this, he was a Vice President of Neurostimulation for Allergan (an AbbVie company), after serving as Co-Founder and CEO of Oculeve, Inc., acquired by Allergan in 2015.

Dr. Ackermann received a BE degree from Vanderbilt University and MS and a Ph.D. degree from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship.